Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?

Affiliations

• ¹ Department of Precision Oncology, University Hospital of Campania "L. Vanvitelli", Naples, Italy. Electronic address: Valerio.nardone@unicampania.it.
• ² Medical Oncology Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania.
• ³ Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania.
• ⁴ Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
• ⁵ Medical Oncology Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy.
• ⁶ Section of Radiation Oncology, Medical School, University of Siena, Siena, Italy.
• ⁷ Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy.
• ⁸ Department of Precision Oncology, University Hospital of Campania "L. Vanvitelli", Naples, Italy.